```html

Quininic Myopathy – A Comprehensive Patient Guide

Overview

Quininic myopathy (also called quinine‑induced myopathy) is a rare, acquired muscle disease caused by toxicity from quinine or quinidine, medications historically used to treat malaria, nocturnal leg cramps, and cardiac arrhythmias. The condition is characterized by muscle weakness, pain, and, in some cases, muscle breakdown (rhabdomyolysis). Because quinine use has dramatically declined in many countries, the overall prevalence is low—estimated at < 0.1 % among individuals who have taken quinine long‑term—but the exact number is unknown due to under‑reporting.

The disease can affect adults of any age but is most commonly reported in middle‑aged women who use quinine for chronic leg cramps. Genetic differences in drug metabolism, renal insufficiency, and concomitant use of other neuro‑toxic drugs increase vulnerability.

Symptoms

Symptoms usually develop weeks to months after the start of quinine therapy, but delayed onset (up to a year) has been described. The clinical picture varies from mild myalgia to severe weakness and rhabdomyolysis.

General muscle complaints

• Myalgia – aching or soreness, often symmetrical in the proximal (shoulder‑pelvic) muscles.
• Muscle cramps – painful, involuntary contractions that may persist despite stopping the drug.
• Fatigue – generalized tiredness that worsens with activity.

Weakness patterns

• Proximal weakness – difficulty rising from a chair, climbing stairs, or lifting objects.
• Distal weakness – less common, may affect hand grip or foot dorsiflexion.
• Facial or bulbar weakness – rare, may cause slurred speech or difficulty swallowing.

Laboratory & systemic signs

• Elevated serum creatine kinase (CK) – often >5× upper limit of normal.
• Myoglobinuria – dark‑colored urine indicating muscle breakdown.
• Electrolyte disturbances (hyperkalemia, hypocalcemia) if rhabdomyolysis occurs.
• Fever, malaise – usually because of secondary inflammation.

Severe manifestations

• Acute rhabdomyolysis leading to acute kidney injury (AKI).
• Respiratory muscle involvement causing shortness of breath.
• Cardiac involvement is extremely rare but has been reported when high‑dose quinine is used intravenously.

Causes and Risk Factors

Quininic myopathy is an iatrogenic condition, meaning it results from medication exposure. The primary cause is toxic accumulation of quinine or its metabolite quinidine in skeletal muscle.

Mechanisms of toxicity

• Direct muscle membrane disruption – quinine interferes with sodium‑potassium channels, leading to depolarization and calcium overload.
• Oxidative stress – quinine metabolites generate free radicals that damage myofibrils.
• Immune‑mediated component – some patients develop auto‑antibodies that mimic inflammatory myopathies.

Key risk factors

• High cumulative dose (> 3 g per month) or prolonged therapy (> 6 months).
• Renal impairment (eGFR < 60 mL/min/1.73 m²) – reduced drug clearance.
• Concomitant use of nephrotoxic or myotoxic drugs (e.g., statins, fibrates, colchicine).
• Older age (> 60 years) – physiologic decline in hepatic metabolism.
• Female sex – epidemiologic data show a 2‑to‑3‑fold higher incidence in women.
• Genetic polymorphisms in CYP3A4/5 enzymes that slow quinine metabolism.

Diagnosis

Diagnosis rests on a combination of clinical suspicion, medication history, laboratory data, and exclusion of other muscle disorders.

Step‑by‑step diagnostic approach

1. Detailed medication review – confirm quinine/quinidine exposure, dose, and duration.
2. Physical examination – assess strength (Medical Research Council scale), tone, and tendon reflexes.
3. Laboratory tests
   • Serum CK – often markedly elevated.
   • Serum aldolase, LDH, and myoglobin – supportive.
   • Renal panel & electrolytes – to detect rhabdomyolysis complications.
   • Autoimmune panel (ANA, anti‑Jo‑1) – to rule out inflammatory myopathies.
4. Electromyography (EMG) & Nerve Conduction Studies – typically reveal myopathic potentials (short-duration, low‑amplitude motor unit potentials) without neuropathic changes.
5. Muscle MRI – shows edema or fatty infiltration in affected muscles, useful when EMG is inconclusive.
6. Muscle biopsy (rarely required) – may show necrotic fibers, inflammatory infiltrates, and vacuolar changes consistent with drug‑induced myopathy.
7. Exclusion of other causes – thyroid dysfunction, endocrine disorders, infections, and genetic muscular dystrophies must be ruled out.

According to the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), a “probable” case is defined by muscle symptoms + CK elevation + documented quinine exposure, while a “definite” case adds EMG/MRI or biopsy confirmation after discontinuation of the drug leads to clinical improvement.

Treatment Options

Management focuses on stopping the offending drug, supportive care, and addressing any complications.

1. Discontinuation of quinine

Immediate cessation is the cornerstone. Symptoms often improve within days to weeks; CK typically normalizes in 2–4 weeks if no severe rhabdomyolysis has occurred.

2. Supportive care

• Hydration – aggressive intravenous isotonic fluids (e.g., 2–3 L/24 h) to prevent AKI.
• Electrolyte management – correct hyper‑ or hypokalemia, monitor calcium.
• Pain control – acetaminophen or low‑dose NSAIDs (avoid if renal function is compromised).
• Physical therapy – gradual strength‑building program once acute phase resolves.

3. Pharmacologic interventions

• Corticosteroids – occasionally used when an immune‑mediated component is suspected, but evidence is limited.
• Statin‑sparing strategies – if the patient requires a statin, consider lower doses or alternative lipid‑lowering agents, as combined therapy raises myopathy risk.

4. Management of rhabdomyolysis complications

• Renal replacement therapy (hemodialysis) for refractory AKI.
• Alkalinization of urine (sodium bicarbonate) in selected cases to prevent myoglobin precipitation.

5. Follow‑up

Re‑check CK and renal labs at 2‑week intervals until stable. Long‑term monitoring is advised for patients with pre‑existing kidney disease.

Living with Quininic Myopathy

While most patients recover fully after drug withdrawal, some may experience lingering weakness. Below are practical tips for daily life:

• Activity pacing – use the “stop‑rest‑repeat” method: work for 5–10 minutes, rest, then resume.
• Assistive devices – a cane or hand‑rail can help with balance during the early recovery phase.
• Nutrition – adequate protein (1.0–1.2 g/kg/day) supports muscle repair; stay hydrated.
• Medication review – inform all healthcare providers about the quinine reaction; maintain an updated medication list.
• Vaccinations – stay up‑to‑date on flu and pneumococcal vaccines to avoid infections that could exacerbate weakness.
• Support networks – patient advocacy groups for drug‑induced myopathies can provide emotional support and up‑to‑date research.

Prevention

Because quininic myopathy is drug‑induced, prevention revolves around prudent prescribing and patient education.

• Limit quinine use – reserve for confirmed malaria or severe refractory leg cramps; avoid over‑the‑counter “night‑cramp” tablets.
• Low‑dose, short‑duration regimens – adhere to FDA‑approved dosing (≤ 200 mg three times daily, total < 1.2 g/day) and discontinue after 2‑4 weeks unless medically necessary.
• Screen for renal/hepatic disease before initiating therapy.
• Medication reconciliation – avoid concurrent myotoxic drugs; if statins are needed, use the lowest effective dose.
• Patient education – teach warning signs (muscle pain, dark urine, rapid weakness) and the importance of early reporting.

Complications

If unrecognized or untreated, quininic myopathy can lead to serious health problems:

• Acute kidney injury – due to myoglobin nephrotoxicity; may progress to chronic kidney disease.
• Permanent muscle weakness – fibrotic replacement of damaged muscle fibers.
• Respiratory failure – rare, but possible when diaphragmatic muscles are involved.
• Cardiac arrhythmias – secondary to electrolyte disturbances (especially hyperkalemia).
• Reduced quality of life – chronic fatigue and functional limitation can affect employment and mental health.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe muscle pain accompanied by swelling.
• Dark, tea‑colored urine indicating myoglobinuria.
• Rapidly rising weakness that interferes with breathing, swallowing, or walking.
• Chest pain, palpitations, or irregular heartbeat.
• Fever > 38.5 °C (101.3 °F) with muscle symptoms.
• Reduced urine output or signs of fluid overload (swelling of ankles, shortness of breath).

These signs may indicate rhabdomyolysis or acute kidney injury, which require immediate treatment.

References

• Mayo Clinic. “Quinine side effects.” mayoclinic.org. Accessed June 2026.
• CDC. “Drug‑Induced Myopathies.” Centers for Disease Control and Prevention. cdc.gov.
• NIH – National Institute of Neurological Disorders and Stroke. “Myopathy Fact Sheet.” ninds.nih.gov.
• American Association of Neuromuscular & Electrodiagnostic Medicine. “Guidelines for the Diagnosis of Drug‑Induced Myopathy.” 2022.
• Cleveland Clinic. “Rhabdomyolysis.” clevelandclinic.org.
• World Health Organization. “Essential Medicines List – Quinine.” WHO, 2023.

```